Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis

References

• de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crépey P, Pitman R, Wilschut JC, Postma MJ. A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Rev Pharmacoecon Outcomes Res. 2017;17(3):249–10. PMID: 28613092. doi:10.1080/14737167.2017.1343145.
   PubMed Web of Science ®Google Scholar
• Caini S, Kusznierz G, Garate VV, Wangchuk S, Thapa B, de Paula Júnior FJ, Ferreira de Almeida WA, Njouom R, Fasce RA, Bustos P, et al. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. PLoS One. 2019;14(9):e0222381. doi:10.1371/journal.pone.0222381.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec. 2012;87(47):461–76.
   PubMedGoogle Scholar
• Pepin S, Dupuy M, Borja-Tabora CFC, Montellano M, Bravo L, Santos J, de Castro J-A, Rivera-Medina DM, Cutland C, Ariza M, et al. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6–35 months: a multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres. Vaccine. 2019;37(13):1876–84. doi:10.1016/j.vaccine.2018.11.074.
   PubMed Web of Science ®Google Scholar
• Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31(5):770–76. doi:10.1016/j.vaccine.2012.11.074.
   PubMed Web of Science ®Google Scholar
• Hendriks J, Hutubessy RCW, Grohmann G, Torelli G, Friede M, Kieny MP. Quadrivalent influenza vaccines in low and middle income countries: cost-effectiveness, affordability and availability. Vaccine. 2018;36(28):3993–97. doi:10.1016/j.vaccine.2018.05.099.
   PubMed Web of Science ®Google Scholar
• Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens JL, et al. Economic analysis of vaccination programs: an ISPOR good practices for outcomes research task force report. Value Health. 2018;21(10):1133–49. doi:10.1016/j.jval.2018.08.005.
   PubMed Web of Science ®Google Scholar
• Ultsch B, Damm O, Beutels P, Bilcke J, Brüggenjürgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, et al. Methods for Health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics. 2016;34(3):227–44. doi:10.1007/s40273-015-0335-2.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. 2nd. Published2019. [Accessed 2020 Dec 8].
   Google Scholar
• Chit A, Roiz J, Aballea S, Chuang J-H. An assessment of the expected cost-effectiveness of quadrivalent influenza vaccines in Ontario, Canada using a static model. PLoS One. 2015;10(7):e0133606. doi:10.1371/journal.pone.0133606.
   PubMed Web of Science ®Google Scholar
• Mennini FS, Bini C, Marcellusi A, Rinaldi A, Franco E. Cost-Effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy. Hum Vaccines Immunother. 2018;14(8):1867–73. doi:10.1080/21645515.2018.1469368.
   PubMed Web of Science ®Google Scholar
• Damm O, Garbe J, Thomas OBH, Alvarez FP, Bellier L, Greiner W, Greiner W. Cost-Effectiveness of quadrivalent influenza vaccination in Germany. Value Health. 2018;21(3):S232. doi:10.1016/j.jval.2018.09.1386.
   Google Scholar
• Crépey P, Redondo E, Díez-Domingo J, Ortiz de Lejarazu R, Martinón-Torres F, Gil de Miguel Á, López-Belmonte JL, Alvarez FP, Bricout H, Solozabal M, et al. From trivalent to quadrivalent influenza vaccines: public health and economic burden for different immunization strategies in Spain. PLoS One. 2020;15(5):e0233526. doi:10.1371/journal.pone.0233526.
   PubMed Web of Science ®Google Scholar
• Crépey P, Boiron L, Araujo RR, Lopez JG, Petitjean A, de Albuquerque Luna EJ. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model. BMC Public Health. 2020;20(1):1374. doi:10.1186/s12889-020-09409-7.
   PubMed Web of Science ®Google Scholar
• Jiang M, Li P, Wang W, Zhao M, Atif N, Zhu S, Fang Y. Cost-Effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China. Vaccine. 2020;38(5):1057–64. doi:10.1016/j.vaccine.2019.11.045.
   PubMed Web of Science ®Google Scholar
• Kim Y-K, Song JY, Jang H, Kim TH, Koo H, Varghese L, Han E. Cost effectiveness of quadrivalent influenza vaccines compared with trivalent influenza vaccines in young children and older adults in Korea. PharmacoEconomics. 2018;36(12):1475–90. doi:10.1007/s40273-018-0715-5.
   PubMed Web of Science ®Google Scholar
• Tsuzuki S, Schwehm M, Eichner M. Simulation studies to assess the long-term effects of Japan’s change from trivalent to quadrivalent influenza vaccination. Vaccine. 2018;36(5):624–30. doi:10.1016/j.vaccine.2017.12.058.
   PubMed Web of Science ®Google Scholar
• Van Bellinghen LA, Marijam A, Tannus Branco de Araujo G, Gomez J, Van Vlaenderen I. Cost-Utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types. Braz J Infect Dis. 2018;22(1):1–10. doi:10.1016/j.bjid.2017.11.004.
   PubMed Web of Science ®Google Scholar
• Jamotte A, Clay E, Macabeo B, Caicedo A, Lopez JG, Bricks L, Romero Prada M, Marrugo R, Alfonso P, Moreno Arévalo B, et al. Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America. Hum Vaccin Immunother. 2017;13(4):877–88. doi:10.1080/21645515.2016.1256928.
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Beigel JH, Guerrero ML, Bellier L, Tamayo R, Cervantes P, Alvarez FP, Galindo-Fraga A, Aguilar-Ituarte F, Lopez JG, et al. Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico. Hum Vaccin Immunother. 2020;16(4):827–35. doi:10.1080/21645515.2019.1678997.
   PubMed Web of Science ®Google Scholar
• Ministry of Health Uruguay (Ministerio de Salud Publica). Vacunación Antigripal y antineumocócica. Published 2018. [Accessed 2020 Sep 28]. https://www.gub.uy/ministerio-salud-publica/comunicacion/comunicados/vacunacion-antigripal-y-antineumococica
   Google Scholar
• World Health Organization. Guidance on the economic evaluation of influenza vaccination. [Accessed 2020 Nov 18]. https://apps.who.int/iris/bitstream/handle/10665/250086/WHO-IVB-16.05-eng.pdf
   Google Scholar
• Bertram M, Lauer J, De Joncheere K, Edejer T, Hutubessy R, Kieny M-P, Hill SR. Cost–effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;64(12):925–30. doi:10.2471/BLT.15.164418.
   Google Scholar
• Cost-Effectiveness Acceptability Curve (CEAC). York Health Economics Consortium. [ Accessed 2016]. https://yhec.co.uk/glossary/cost-effectiveness-acceptability-curve-ceac/.
   Google Scholar
• DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012;31(1):49–57. doi:10.1016/j.vaccine.2012.10.084.
   PubMed Web of Science ®Google Scholar
• United Nations. Record view, life expectancy at birth for both sexes combined (years). Published 2019. [Accessed 2020 Sep 28]. https://population.un.org/wpp/Download/Standard/Mortality/
   Google Scholar
• World Health Organization. FluNet. https://www.who.int/influenza/gisrs_laboratory/flunet/en/. [Accessed 2020 Sep 30].
   Google Scholar
• Tran BX, Ohinmaa A, Nguyen LT. Quality of life profile and psychometric properties of the EQ-5D-5L in HIV/AIDS patients. Health Qual Life Outcomes. 2012;10(1):132. doi:10.1186/1477-7525-10-132.
   PubMedGoogle Scholar
• Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012;30(11):1993–98. doi:10.1016/j.vaccine.2011.12.098.
   PubMed Web of Science ®Google Scholar
• CINVE Consultora Salud (CINVE Health Consultancy). ‘Gasto Medio por Individuo 2010-2018' (Average spending per individual 2010-2018). [Unpublished data presented at Sector Inform presentation]. 2019.
   Google Scholar
• Pan American Health Organization. PAHO revolving fund vaccine prices for 2019. Published 2019. [Accessed 2020 Sep 30]. https://www.paho.org/en/documents/paho-revolving-fund-vaccine-prices-2019
   Google Scholar
• Van Wilder L, Rammant E, Clays E, Devleesschauwer B, Pauwels N, De Smedt D. A comprehensive catalogue of EQ-5D scores in chronic disease: results of a systematic review. Qual Life Res. 2019;28(12):3153–61. doi:10.1007/s11136-019-02300-y.
   PubMed Web of Science ®Google Scholar
• Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, Adebayo OM, Afarideh M, Agarwal SK, Agudelo-Botero M; GBD Chronic Kidney Disease Collaboration; Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709–33. doi:10.1016/S0140-6736(20)30045-3.
   PubMed Web of Science ®Google Scholar
• Hosseini M, Almasi-Hashiani A, Sepidarkish M, Maroufizadeh S. Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis. Respir Res. 2019;20(1):229. doi:10.1186/s12931-019-1198-4.
   PubMed Web of Science ®Google Scholar
• Loukine L, Waters C, Choi BC, Ellison J. Impact of diabetes mellitus on life expectancy and health-adjusted life expectancy in Canada. Popul Health Metr. 2012;10(1):7. doi:10.1186/1478-7954-10-7.
   PubMedGoogle Scholar
• Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA. Cost-Effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother. 2014;10(5):1171–80. doi:10.4161/hv.28221.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2012;2012:Cd004879.
   PubMedGoogle Scholar
• Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36–44. doi:10.1016/S1473-3099(11)70295-X.
   PubMed Web of Science ®Google Scholar
• Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, Tashkandi M, Bauch CT, Loeb M. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11(1):153. doi:10.1186/1741-7015-11-153.
   PubMedGoogle Scholar
• Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010;3:Cd004876. doi:10.1002/14651858.CD001269.
   PubMed Web of Science ®Google Scholar
• Ministry of Health Uruguay (Ministerio de Salud Publica). 2da encuesta nacional de factores de riesgo de enfermedades no transmisibles (National survey of risk factors for noncommunicable diseases). Published 2019. [ Accessed 2020 Sep 30].
   Google Scholar
• Uruguay Pharmacy Center (Centro de Farmacias del Uruguay). [Accessed 2020 Feb 21]. http://cfu.org.uy/medicamentos.html
   Google Scholar
• Drummond MSM, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th. Oxford: Oxford University Press; 2015.
   Google Scholar
• Aoki FY, Fleming DM, Griffin AD, Lacey LA, Edmundson S. Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group. Pharmacoeconomics. 2000;17(2):187–95. doi:10.2165/00019053-200017020-00007.
   PubMed Web of Science ®Google Scholar
• National Institute of Statistics of Uruguay. Actividad, Empleo y Desempleo. http://www.ine.gub.uy/actividad-empleo-y-desempleo. Published 2018. [Accessed 2020 Sep 30].
   Google Scholar
• Castiglia A, Echagüe T. ‘Ministro de Trabajo y Seguridad Social Mtro. Ernesto Murro’, Unidad Estadística del Trabajo y la Seguridad Social. Published 2019. [Accessed 2020 Sep 30]. https://www.gub.uy/ministerio-trabajo-seguridad-social/sites/ministerio-trabajo-seguridad-social/files/documentos/publicaciones/SMN%20y%20salarios%20bajos%20en%20Uruguay%20-%20sueldo%20base%20%28g126%29_actualizado_2017_6_febrero-1.pdf
   Google Scholar
• Augustovski F, Rey-Ares L, Irazola V, Garay OU, Gianneo O, Fernández G, Morales M, Gibbons L, Ramos-Goñi JM. An EQ-5D-5L value set based on Uruguayan population preferences. Qual Life Res. 2016;25(2):323–33. doi:10.1007/s11136-015-1086-4.
   PubMed Web of Science ®Google Scholar
• Arrospide A, Machón M, Ramos-Goñi JM, Ibarrondo O, Mar J. Inequalities in health-related quality of life according to age, gender, educational level, social class, body mass index and chronic diseases using the Spanish value set for Euroquol 5D-5L questionnaire. Health Qual Life Outcomes. 2019;17(1):69. doi:10.1186/s12955-019-1134-9.
   PubMedGoogle Scholar
• Yang F, Lau T, Lee E, Vathsala A, Chia KS, Luo N. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD). Eur J Health Econ. 2015;16(9):1019–26. doi:10.1007/s10198-014-0664-7.
   PubMed Web of Science ®Google Scholar
• Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, Raboud JM, Krahn M. Economic appraisal of Ontario’s Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med. 2010;7(4):e1000256. doi:10.1371/journal.pmed.1000256.
   PubMed Web of Science ®Google Scholar
• Chi YL, Blecher M, Chalkidou K, Culyer A, Claxton K, Edoka I, Glassman A, Kreif N, Jones I, Mirelman AJ, et al. What next after GDP-based cost-effectiveness thresholds? Gates Open Res. 2020;4:176. doi:10.12688/gatesopenres.13201.1.
   PubMedGoogle Scholar
• Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–24. doi:10.2471/BLT.14.138206.
   PubMed Web of Science ®Google Scholar
• Bernales-Baksai P. Tackling segmentation to advance universal health coverage: analysis of policy architectures of health care in Chile and Uruguay. Int J Equity Health. 2020;19(1):106. doi:10.1186/s12939-020-01176-6.
   PubMed Web of Science ®Google Scholar